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Abstract Patients who recover from aneurysmal sub-
arachnoid haemorrhage (SAH) often remain disabled or
have persisting symptoms with a reduced quality of life
(QoL). We assessed functional outcome and QoL 5 and
12.5 years after SAH. In a consecutive series of 64 patients
with mean age at SAH of 51 years, initial outcome
assessments had been performed at 4 and 18 months after
SAH. At the initial and current outcome assessments,
functional outcome was measured with the modiﬁed Ran-
kin Scale (mRS) and QoL with the SF-36 and a visual
analogue scale (VAS). We studied the change in outcome
measurements over time. We used the non-parametric
Wilcoxon test to compare differences in mRS grades and
calculated differences with corresponding 95% conﬁdence
intervals in the domain scores of the SF-36 and the VAS.
After 5 years, seven patients had died and ﬁve patients had
missing data. Compared with the 4-month follow-up, the
mRS had improved in 29 of the 52 patients, remained
similar in 19 patients. The overall QoL (SF-36 domains and
VAS score) was better. At 12.5 years an additional six
patients had died. Compared to the 4-month study, 25 of
the 46 remaining patients had improved mRS, 12 had
remained the same and in nine patients the mRS had
worsened. Between the 5 and the 12.5 years follow-up, the
improvement in mRS had decreased but patients reported
overall a better QoL. Among long-time survivors, QoL
may improve more than a decade after SAH.
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Introduction
Subarachnoid haemorrhage (SAH) from a ruptured aneu-
rysm carries a poor prognosis. Within the ﬁrst month after
the haemorrhage, one-third of the patients die [1]. Of those
who survive the initial weeks, one-third are disabled in the
ﬁrst month after the haemorrhage [1, 2], but recovery
continues after this period. In a cohort study 4 and
18 months after the haemorrhage, half the patients had
improved on the modiﬁed Rankin Scale (mRS) with at least
one point [2, 3]. Of the patients who were independent
(mRS \4) at 18 months after the haemorrhage, many
experienced a reduced quality of life (QoL). Because most
patients are between 40 and 60 years old at the time of the
haemorrhage, functional disability and QoL may further
improve. If disability and QoL remain reduced in the long
term, this can have considerable impact for patients and for
health economics. We assessed the extent of changes in
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Methods
We studied a prospectively collected, consecutive series of
98 patients with aneurysmal SAH admitted to the Univer-
sity Medical Centre Utrecht between September 1995 and
September 1996. Aneurysmal SAH was diagnosed if CT
scanning conﬁrmed the presence of subarachnoid blood
and if an aneurysm was found on conventional-, CT- or
MR-angiography. Patients with a non-aneurysmal cause of
the SAH were excluded. Thirty of the 98 enrolled patients
had died during their clinical course, two had been exclu-
ded from the previous study because they did not speak
Dutch and two patients had declined participation in the
study. Thus, our study consisted of 64 patients. Between 4
and 18 months three patients had died [3], but their deaths
were not directly related to the SAH.
For the 5- and 12.5-year outcome assessments, we ﬁrst
contacted the general practitioner of the patient to ﬁnd out
if the patient was still living. If not, we asked for the date
and cause of death. If the address of the patient was
unknown to the general practitioner, we veriﬁed it via the
municipal archives. Patients who had no telephone were
sent a letter and asked to call us. We asked the patient by
telephone to answer the same questionnaire as the one we
used at the 4- and 18-month follow-ups.
Instruments
For assessment of disability, we applied the mRS [4], a
frequently used functional outcome instrument in stroke.
The mRS is a 6-point handicap scale that focuses on
restrictions in lifestyle. The Rankin scale is easy to
administer, available in a validated Dutch version and
reliable in terms of interobserver agreement [4]. This Dutch
version is also validated for telephone assessment [5]. For
assessment of QoL we used the medical outcome study
short form 36 (SF-36), a validated instrument to assess
general QoL and a visual analogue scale (VAS). The SF-36
is brief (5–10 min) and measures eight health-related
domains: physical functioning (10 items), role limitations
due to physical health problems (4 items), bodily pain (2
items), general health perceptions (5 items), vitality (4
items), social functioning (2 items), role limitations due to
emotional problems (3 items) and general mental health (5
items). The SF-36 scores are calculated by assignment of
predeﬁned weights to the different items and range per
domain from 0 (maximum reduction in QoL) to 100 (no
reduction in QoL). The validity and reliability of the SF-36
have been studied extensively, including the Dutch version
[6–9]. The VAS ranged from 0 (poor) to 100 (excellent)
just by asking the patient to put a mark on this scale for
overall well-being.
Data collection
All questionnaires were administered in a semi-structured
telephone interview by one experienced research nurse
(PG). We started the interview with a short introduction
and reminder of the 4- and 18-month QoL studies. If the
patient was not able to answer the questions because of
severe cognitive deﬁcits, we only recorded the Rankin
grade of the patient based on information obtained from the
partner.
Data analyses
To compare differences in Rankin grades and QoL scores
between 4 months and 5 years, 4 months and 12.5 years,
and 5 years and 12.5 years we used the non-parametric
Wilcoxon test. We calculated differences in the domain
scores of the SF-36 and of the VAS; the corresponding
95% conﬁdence intervals (95% CI) were based on the
paired t test.
Results
Of the 64 patients with a 4-month follow-up, 45 (70%)
were women. The mean age at that time was 51 (± SD
12.6) years. Fifty-six patients (88%) were in good clinical
condition on admission, as assessed with the World Fed-
eration of Neurological Surgeons (WFNS) [10] scale
(WFNS I n = 35; WFNS II n = 16; WFNS III n = 5), and
eight were in poor clinical condition (WFNS IV n = 4;
WFNS V n = 4). At time of the 18-month follow-up the
study population consisted of 61 patients.
For the 5-year outcome assessment, the mean period of
follow-up was 5.5 years after the SAH (range
5.3–5.7 years). Four patients (3 women, 1 man) had died
between the 18-month and 5-year outcome assessment. In
one patient, the general practitioner said that the cause of
death was an unveriﬁed SAH that had occurred abroad, and
in three it was cancer. We could no longer contact another
four patients, as no telephone number was available and the
patients did not respond to our letter. Another patient was
found, contacted by telephone, but was too deaf to be
interviewed. The remaining 52 patients could be contacted
and all participated in the 5-year outcome assessment.
For the 12.5-year follow-up, the mean follow-up was
13.3 years after SAH (range 12.8–13.5 years). An addi-
tional six patients had died between the 5- and 12.5-year
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not interviewed at the 5-year outcome assessment were
again not interviewed but were still living. One patient
declined further participation. The remaining 46 patients,
34 women and 12 men, could be contacted by telephone for
the 12.5-year outcome assessment.
Functional outcome
Figure 1a provides an overview of the mRS grade distri-
bution among patients who were living, deceased or with
missing data at the four outcome assessments. Figure 1b
shows the mRS grade distribution among patients who
were living and the patients who had died at each outcome
assessment and Fig. 1c shows the mRS grade distribution
at each outcome assessment for only those patients who
were living. The changes in mRS grades between 4 months
and 5 years, 4 months and 12.5 years, and 5 and 12.5 years
are shown in Tables 1, 2 and 3. In the 4-month and 5-year
follow-up, 19 patients remained the same and 29 patients
improved. In 18 of these 29 patients the mRS had improved
one point, in 10 it had improved two points, and in one
patient it had improved three points. In 12 patients the mRS
grade remained the same at the 4-month and the 12.5-year
follow-ups. In 25 patients the mRS grade improved, 16 by
one point, seven by two points, and two patients by three
points. Between the 5- and the 12.5-year follow-up the
improvement declined with one patient reporting a heart
operation, one a myocardial infarction and another patient
a colon cancer. In 30 patients the mRS grade remained the
same at 5- and 12.5-year follow-up.
Quality of life in patients
Table 4 shows the differences for the domains of the SF-36
and the VAS score between 4 months and 5 years,
4 months and 12.5 years, and 5 years and 12.5 years. For
the SF-36 domains, role limitations because of physical
health problems and role limitations because of emotional
problems, the scores are clearly higher (improvement) after
A
B
C
Fig. 1 a Proportion of
surviving patients with
distribution of mRS grades,
deceased and missing patients.
b Proportion of surviving
patients with distribution of
mRS grades, deceased patients.
c Proportion of surviving
patients with distribution of
mRS grades
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1235 years than at 4 months and further increased after a 12.5-
year follow-up. The physical functioning and general
mental health scores had worsened. Figure 2 shows the
VAS scores after 4-, 18-month, 5- and 12.5-year follow-
ups. Also, surviving long-term follow-up patients reported
improvement in their wellbeing compared with their score
at 4 months. At the 5-year follow-up, most patients
reported their functional, social and physical problems as
SAH-related: persistent tiredness, slowness, impairment of
memory, change in personality, headache and concentra-
tion problems.
Discussion
This study shows that recovery among patients who have
survived an episode of SAH continues in the long-term.
Between 4 months and 5 years after the haemorrhage,
half the surviving patients showed an improvement on the
mRS of at least one point. Between 5- and 12.5-year
follow-ups there was no further improvement with even a
slight decrease in functional outcome. At the 12.5-year
follow-up, patients reported the functional status to be
‘‘normal for my age’’, despite a decline in physical
functioning. They attributed this reduced physical func-
tioning to other diseases they had, such as osteoporosis,
emphysema, cancer, diabetes, heart failure, and impair-
ment of vision and hearing. Despite a reduction in
physical functioning between the 5- and 12.5-year out-
come assessments, QoL had improved over this period.
This suggests that patients continue to adapt and improve
while coping with restrictions in functioning. Psycholog-
ical adaptation has been described also in other chronic
diseases [11]. The overall good QoL indicates an
improved appreciation of life long after a life-threatening
illness. Similar observations have been done in long-term
survivors of TIA or minor ischemic stroke who have an
overall QoL not much different than the general popula-
tion [12].
Some limitations of the current study have to be men-
tioned. To assess disability in terms of functional outcome
and QoL, we used the mRS, the SF-36 and a VAS. These
outcome measurements had also been used before at the 4-
and 18-month follow-ups, before the current study was
developed. The sickness impact proﬁle (SIP) was also used
in the initial outcome assessments, and had similar out-
comes at the 4- and 18-month time points but did not
discriminate between patients with improved or static
Table 1 Modiﬁed Rankin
grades at 4-month and 5-year
follow-ups
5 years Total
0 1 2 3 4 5 Dead Missing
4 months
0 72– –– – – – 9
1 351 2– – 1 1 1 3
2 363 –– – 4 1 1 7
3 152 2– – – 1 1 1
4 ––1 51 – – 2 9
5 ––– 11 1 2 – 5
Total 14 18 7 10 2 1 7 5 64
Table 2 Modiﬁed Rankin
grades at 4-month and 12.5-year
follow-ups
12.5 years Total
0 1 2 3 4 5 Dead Missing
4 months
04 2 – – – – 21 9
14 2 3 1 – – 21 1 3
24 4 3 2 – – 4– 1 7
31 2 5 1 – – 11 1 1
4– 1 – 2 1 1 22 9
5– – – 1 1 1 2– 5
Total 13 11 11 7 2 2 13 5 64
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time-consuming. For both of these reasons we decided not
to continue using the SIP for the 5-year and the 12.5-year
follow-ups. A disease speciﬁc QoL list was not used in
1995. Therefore, we cannot distinguish between disability
remaining from the SAH and disability as a result of other,
age-related diseases. Another limitation is that the initial
cohort of 64 patients is relatively small and all interviews
were administered by telephone. However, we
demonstrated that telephone assessment of the mRS with a
structured interview has as good results as face-to-face
assessment [5]. Strong points are that, at the 12.5-year time
point, there was no loss to follow-up and all interviews
were performed by the same research nurse. As far as we
know, this is the ﬁrst attempt to assess changes in func-
tional outcome and QoL for longer than a decade in
patients with SAH. Therefore, we could not compare our
results with those from other studies. We conclude that it is
Table 3 Modiﬁed Rankin grades at 5- and 12.5-year follow-ups
12.5 years Total
0 1 2 3 4 5 Dead Missing
5 years
0 9 1 – 1––2 1 1 4
1 4 9 4 1––– – 1 8
2 – 1 6 –––– – 7
3 – – 1 41–4 – 1 0
4 – – – –11– – 2
5 – – – ––1– – 1
Dead – – – – – – 7 – 7
Missing – – – 1 – – – 4 5
Total 13 11 11 7 2 2 13 5 64
Wilcoxon tests for comparisons of mRS: 4 months–5 years, p = 0.12; 4 months–12.5 years, p = 0.58; 5–12.5 years, p = 0.01
m Rankin scale: 0, no symptoms at all; 1, no signiﬁcant disability despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately
severe disability; 5, severe disability
Table 4 Differences over time in SF-36 and VAS
Means Differences (95%CI)
4 months 5 years 12.5 years 4 months–5 years
a 4 months–12.5 years
b 5–12.5 years
b
SF-36
PF 68.7 74.7 77.2 6.5 (0.6 to 12.4) 5.9 (-0.3 to 11.4) -1.7 (-8.0 to 4.6)
RP 24.6 62.5 91.3 34.8 (18.9 to 50.6) 64.0 (50.9 to 77.1) 25.0 (7.9 to 42.1)
BP 75.1 85.9 92.2 7.6 (1.2 to 13.9) 14.4 (6.3 to 22.6) 6.0 (-1.7 to 13.6)
GH 70.7 73.4 71.9 0.5 (-6.4 to 7.4) -1.2 (-8.2 to 5.8) -4.1 (-9.4 to 1.1)
VT 60.1 59.8 65.3 -2.2 (-7.9 to 3.5) 3.4 (-2.5 to 9.4) 3.9 (-0.5 to 8.3)
SF 66.3 80.7 90.4 12.0 (2.9 to 21.0) 22.6 (13.1 to 32.0) 6.4 (-3.0 to 15.8)
RE 59.5 81.3 96.9 18.8 (3.3 to 34.4) 39.0 (25.9 to 52.1) 13.8 (1.4 to 26.3)
MH 70.1 70.4 73.8 0.4 (-5.0 to 5.9) 4.5 (-1.3 to 10.3) 2.8 (-1.2 to 6.8)
PCS 42.8 48.6 51.1 4.7 (2.1 to 7.4) 6.7 (3.8 to 9.6) 1.5 (-1.2 to 4.2)
MCS 47.2 49.4 52.7 1.5 (-1.8 to 4.9) 5.9 (2.7 to 9.1) 2.8 (0.2 to 5.8)
VAS 59 72 76 11 (5 to 17) 16 (9 to 23) 3 (-6t o7 )
PF physical functioning, RP role limitations because of physical health problems, BP bodily pain, GH general health perceptions, VT vitality, SF
social functioning, RE role limitations because of emotional problems, MH general mental health, PCS physical summary scale, MCS mental
summary scale
a 46 pairs;
b41 pairs
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123important for patient care to inform patients and their
partners that QoL may improve more than a decade after
SAH. In further studies the relationship between functional
outcome and QoL should be assessed by long-term follow-
up studies, as well as determinants of good outcome long
after the SAH.
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